This content requires Adobe Flash Player version
Either you do not have Adobe Flash Player installed,
or your version is too old,
or there is a problem with your Flash installation and we were unable to detect it.
Insulin is the treatment of choice in Cystic Fibrosis Related Diabetes (CFRD). The treatment regime should be tailored to meet the needs of the patient in relation to the stage of the disease, individual risk factors and specific treatment goals. Oral anti-diabetic agents are currently not recommended for the treatment of CFRD due to the lack of a robust evidence base. The CF Trust does state that sulphonylureas and glitinides may be used when a patient is unable (for example, due to social, psychological or physical barriers) to commence on insulin.